These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7416748)

  • 21. Resistance to gentamicin and amikacin of gram-negative organisms isolated from horses.
    Orsini JA; Benson CE; Spencer PA; Van Miller E
    Am J Vet Res; 1989 Jun; 50(6):923-5. PubMed ID: 2669575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Stamm JM; Hanson CW; Chu DT; Bailer R; Vojtko C; Fernandes PB
    Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro antibacterial activity of apalcillin on aerobic bacteria and the regression curve].
    Soussy CJ; Duval J; Chanal M; Sirot D; Bergogne-Bérézin E; Joly-Guillou ML; Malbruny B; Morel C
    Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):660-4. PubMed ID: 3054743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of bacterial multiplication by the iron chelator deferoxamine: potentiating effect of ascorbic acid.
    van Asbeck BS; Marcelis JH; Marx JJ; Struyvenberg A; van Kats JH; Verhoef J
    Eur J Clin Microbiol; 1983 Oct; 2(5):426-31. PubMed ID: 6416837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftriaxone: a summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-micrograms disks.
    Jones RN; Barry AL; Thornsberry C
    Diagn Microbiol Infect Dis; 1983 Dec; 1(4):295-311. PubMed ID: 6321093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of the in vitro spectrum of activity of imipenem.
    Jones RN
    Am J Med; 1985 Jun; 78(6A):22-32. PubMed ID: 3890537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vitro activity of azthreonam on hospital Gram-negative bacilli. Results of a multicenter study].
    Deforges L; Le Van Thoi J; Soussy CJ; Duval J; Thabaut A; Meyran M; Acar JF; Kitzis MD; Chanal M; Cluzel M; Morel C
    Pathol Biol (Paris); 1983 Jun; 31(6):488-91. PubMed ID: 6348655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.
    Jones RN; Thornsberry C
    Rev Infect Dis; 1982; 4 Suppl():S300-15. PubMed ID: 6294779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibacterial effect of zinc oxide in vitro.
    Söderberg TA; Sunzel B; Holm S; Elmros T; Hallmans G; Sjöberg S
    Scand J Plast Reconstr Surg Hand Surg; 1990; 24(3):193-7. PubMed ID: 2281305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rifampin: spectrum of antibacterial activity.
    Thornsberry C; Hill BC; Swenson JM; McDougal LK
    Rev Infect Dis; 1983; 5 Suppl 3():S412-7. PubMed ID: 6635433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin with a broad antibacterial spectrum.
    Hata K; Otsuki M; Nishino T
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1894-901. PubMed ID: 1416879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative antibacterial activity of the aminothiazolyl cephalosporin RU 29,246.
    Qadri SM; Ueno Y; Saldin H; Tullo DD; Lee GC
    Chemotherapy; 1993; 39(3):175-81. PubMed ID: 8508687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antimicrobial activities of polymyxin B against clinically isolated microbial strains. Results of MIC determination including high concentrations].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1993 Oct; 46(10):884-95. PubMed ID: 8254890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical laboratory approach to estimate effective administrative dose of minocyclin. Reevaluation of in vitro MIC break points in disc susceptibility test].
    Uete G; Matsuo K; Uete T
    Jpn J Antibiot; 1990 Sep; 43(9):1545-58. PubMed ID: 2262962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro evaluation of lomefloxacin activity in Colombia.
    Trujillo H; Mejia GI; Castrillon L; Gomez C
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):51S-52S. PubMed ID: 2791498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of 2-acetylpyridine and 2-acetylquinoline thiosemicarbazones tested in vitro in combination with other antituberculous drugs.
    Collins FM; Klayman DL; Morrison NE
    Am Rev Respir Dis; 1982 Jan; 125(1):58-60. PubMed ID: 6175259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of azthreonam, a monobactam antibiotic.
    Jacobus NV; Ferreira MC; Barza M
    Antimicrob Agents Chemother; 1982 Nov; 22(5):832-8. PubMed ID: 6891198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro antibacterial activity of a new oral cephalosporin, ceftibuten. Results of a multicenter study].
    Soussy CJ; Meyran M; Chanal M; Reverdy ME; Kitzis MD; Derlot E
    Pathol Biol (Paris); 1991 May; 39(5):396-402. PubMed ID: 1909017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical laboratory approach to estimating the effective administration dose of imipenem/cilastatin. Evaluation of the disk susceptibility test and its interpretation system].
    Matsuo K; Uete T
    Jpn J Antibiot; 1989 Nov; 42(11):2377-92. PubMed ID: 2621780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.
    Fu KP; Neu HC
    Antimicrob Agents Chemother; 1978 Mar; 13(3):358-67. PubMed ID: 122519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.